BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, has announced significant research presentations at two major oncology conferences, demonstrating the company's expanding role in advancing precision medicine for cancer patients.
Breakthrough Breast Cancer Research at SABCS 2024
BostonGene will present three abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) this December, showcasing innovative approaches to breast cancer treatment through advanced molecular profiling.
"We're excited to present our research at the 2024 SABCS, underscoring BostonGene's commitment to leveraging molecular profiling as a transformative tool in breast cancer treatment," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our findings in transcriptomic classification aim to pave the way for more effective treatment pathways, establishing new benchmarks for precision oncology."
The company's first presentation compares next-generation sequencing (NGS) with fluorescence in situ hybridization (FISH) in assessing ERBB2 (HER2) alterations in breast cancer. The research demonstrated that NGS detected potentially clinically relevant ERBB2 mutations in non-amplified samples and revealed heterogeneity among ERBB2 amplifications that traditional FISH testing might miss. These nuanced insights could significantly impact personalized treatment strategies.
In collaboration with MD Anderson Cancer Center, BostonGene will present findings on antibody-drug conjugate (ADC) target expression in invasive lobular carcinoma (ILC). Using RNA-seq analysis of 82 cell surface proteins, researchers identified distinct expression landscapes across different ILC subtypes, highlighting the importance of subtype-specific approaches for optimal ADC-based treatment efficacy and safety.
The third presentation, conducted with the University of Miami, focuses on using circulating tumor DNA (ctDNA) as a predictive marker for early treatment changes in metastatic breast cancer patients. This phase 2 randomized study incorporated BostonGene's liquid biopsy test to validate the clinical utility of serial ctDNA monitoring, demonstrating its ability to detect molecular progression before clinical manifestation.
Immunotherapy Advancements at SITC Annual Meeting
BostonGene will also present six posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in November, showcasing collaborative research with leading cancer centers.
The company's multiplex immunofluorescence pipeline combines cell segmentation and spatial analysis to identify immune cell types in various tumor microenvironment (TME) subtypes across multiple cancer types, revealing the diverse nature of TME landscapes and the necessity for tailored immunotherapeutic approaches.
Two studies focus on comprehensive genomic profiling (CGP) in sarcomas. One study, conducted with MD Anderson Cancer Center, revealed genetic changes critical for targeted therapy selection in angiosarcomas, while another collaboration with Massachusetts General Hospital Cancer Center and Sarcoma Oncology Center uncovered over 1,000 genetic alterations across 47 histological subtypes among 356 sarcoma patients, with approximately 400 actionable findings associated with approved therapies or clinical trial inclusion criteria.
BostonGene's machine learning platform for analyzing blood-derived cell-free RNA (cfRNA) offers unprecedented insights into tumor biology and can potentially characterize any tumor-associated transcriptomic changes reflected in the cfRNA.
The company is also developing a composite signature for predicting immune-related adverse events (irAEs) in advanced melanoma patients treated with immune checkpoint blockade. Using flow cytometry and bulk RNA-seq to analyze blood cells collected before treatment, researchers constructed irAE signatures that can potentially identify patients likely to develop these severe side effects, enabling timely mitigation strategies.
In collaboration with multiple cancer centers, BostonGene used RNA sequencing to uncover the expression landscape of potential antibody-drug conjugate targets in sarcomas, particularly those with low expression in normal tissues. The findings revealed many genes that are precluded from existing clinical trials, underscoring the need to advance clinical trials and precision oncology in sarcoma therapies.
Transforming Cancer Care Through AI and Molecular Profiling
Founded in 2015, BostonGene has consistently pushed the boundaries of innovation in computational biology and precision medicine. The company's AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets, and recommend the most effective treatments.
With advanced bioanalytics, an indication-specific cancer library, and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, BostonGene delivers precise, clinically validated insights that drive precision medicine and advance oncology research.
The research being presented at these prestigious conferences demonstrates BostonGene's commitment to improving patient care through innovative approaches to molecular profiling and precision oncology, potentially transforming treatment strategies for breast cancer, sarcomas, and other malignancies.
